STAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal

English health authorities reached an agreement on Thursday to provide AstraZeneca’s breast cancer drug through the National Health Service. The decision concludes a years-long dispute regarding the drug's availability within the U.K. public health system.

The agreement is a direct result of a drug pricing deal between the United Kingdom and the United States. The resolution addresses previous concerns regarding AstraZeneca’s commitment to the U.K. market and expands patient access to the treatment.